LL-37
Symbol Ll · MW 4493 Da
Human cathelicidin antimicrobial peptide active across bacteria, viruses and fungi.
- Discovered
- 1995
- Half-life
- 1 hour
- Approval
- Not FDA-approved
Quick facts
- Category
- Recovery
- Route
- Injectable
- Molecular weight
- 4493 Da
- Half-life
- 1 hour
- Discovered
- 1995
- Approval status
- Not FDA-approved
Reported effects
- Broad antimicrobial
- Wound defense
- Inflammation control
Overview
LL-37 is a naturally occurring antimicrobial peptide that plays an important role in the body's innate immune defense system. It helps protect against bacteria and other microbes while also participating in wound healing, inflammation signaling, and tissue repair. LL-37 is commonly studied for infection defense, wound recovery, biofilm disruption, and immune support. As a recovery peptide, it is especially interesting because it combines antimicrobial activity with repair-related functions. LL-37 is not simply an antibiotic alternative; it is a complex immune peptide involved in both defense and healing pathways.
Evidence context
LL-37 evidence summary
Human clinical evidence
LL-37 has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
LL-37 may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for LL-37 as Not FDA-approved. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Topical / Injectable
- Typical Dosage
- No established approved dosage; commonly referenced research range is 100–500 mcg daily
- Typical Frequency
- Once daily during short research cycles
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on LL-37.
Internal links
Related peptides
Frequently asked questions
What category is LL-37 in?
LL-37 is listed in the Recovery category on Peptidic.
What route is LL-37 associated with?
LL-37 is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is LL-37 approved?
Peptidic lists the approval status for LL-37 as: Not FDA-approved. Approval details can vary by indication and jurisdiction.
Interested in LL-37?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01